Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients

Alison Gail Freifeld, Philip Pizzo

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background. Empiric antibiotic therapy has become a standard of care for the febrile neutropenic patient. Many clinical trials over the previous three decades have demonstrated that a variety of antibiotic combinations and more recently potent antibiotic monotherapies may preserve the patient through the critical time of fever and neutropenia. Recently attempts have been made to identify 'low risk' patients who may not require traditional, intensive, hospitalized intravenous antimicrobial therapy. Therefore the need for new treatment alternatives for the febrile neutropenic pediatric cancer patient in particular revolves around the desire for less complex regimens, agents with minimal toxicity and expense and the option of an oral formulation for outpatient management. Objective. Fluoroquinolones, especially ciprofloxacin and ofloxacin, are examined in this paper as potential oral alternatives for managing the low risk neutropenic pediatric cancer patient population. Attention must be paid to their antibacterial spectra, however, and in some cases fluoroquinolones should be combined with a second agent for additional Gram-positive coverage. Results. Several studies, including one ongoing trial at the National Cancer Institute, have shown the potential benefits of oral fluoroquinolone therapy among low risk febrile neutropenic patients. Joint complaints in children after ciprofloxacin therapy in the National Cancer Institute trial thus far have been minimal, reversible and felt to be unrelated to ciprofloxacin treatment. Conclusion. The use of outpatient therapy, such as the fluoroquinolones, to manage febrile neutropenic episodes must be approached with caution and should be undertaken only in selected low risk patients.

Original languageEnglish (US)
Pages (from-to)140-146
Number of pages7
JournalPediatric Infectious Disease Journal
Volume16
Issue number1
DOIs
StatePublished - Jan 1 1997

Fingerprint

Febrile Neutropenia
Fluoroquinolones
Pediatrics
Fever
Ciprofloxacin
Neoplasms
National Cancer Institute (U.S.)
Anti-Bacterial Agents
Therapeutics
Outpatients
Ofloxacin
Standard of Care
Neutropenia
Joints
Clinical Trials
Population

Keywords

  • Fluoroquinolones
  • cancer
  • empiric treatment
  • febrile neutropenia
  • pediatric

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. / Freifeld, Alison Gail; Pizzo, Philip.

In: Pediatric Infectious Disease Journal, Vol. 16, No. 1, 01.01.1997, p. 140-146.

Research output: Contribution to journalArticle

@article{96f739a3c6eb473ba6972d6c13ed1854,
title = "Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients",
abstract = "Background. Empiric antibiotic therapy has become a standard of care for the febrile neutropenic patient. Many clinical trials over the previous three decades have demonstrated that a variety of antibiotic combinations and more recently potent antibiotic monotherapies may preserve the patient through the critical time of fever and neutropenia. Recently attempts have been made to identify 'low risk' patients who may not require traditional, intensive, hospitalized intravenous antimicrobial therapy. Therefore the need for new treatment alternatives for the febrile neutropenic pediatric cancer patient in particular revolves around the desire for less complex regimens, agents with minimal toxicity and expense and the option of an oral formulation for outpatient management. Objective. Fluoroquinolones, especially ciprofloxacin and ofloxacin, are examined in this paper as potential oral alternatives for managing the low risk neutropenic pediatric cancer patient population. Attention must be paid to their antibacterial spectra, however, and in some cases fluoroquinolones should be combined with a second agent for additional Gram-positive coverage. Results. Several studies, including one ongoing trial at the National Cancer Institute, have shown the potential benefits of oral fluoroquinolone therapy among low risk febrile neutropenic patients. Joint complaints in children after ciprofloxacin therapy in the National Cancer Institute trial thus far have been minimal, reversible and felt to be unrelated to ciprofloxacin treatment. Conclusion. The use of outpatient therapy, such as the fluoroquinolones, to manage febrile neutropenic episodes must be approached with caution and should be undertaken only in selected low risk patients.",
keywords = "Fluoroquinolones, cancer, empiric treatment, febrile neutropenia, pediatric",
author = "Freifeld, {Alison Gail} and Philip Pizzo",
year = "1997",
month = "1",
day = "1",
doi = "10.1097/00006454-199701000-00039",
language = "English (US)",
volume = "16",
pages = "140--146",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients

AU - Freifeld, Alison Gail

AU - Pizzo, Philip

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Background. Empiric antibiotic therapy has become a standard of care for the febrile neutropenic patient. Many clinical trials over the previous three decades have demonstrated that a variety of antibiotic combinations and more recently potent antibiotic monotherapies may preserve the patient through the critical time of fever and neutropenia. Recently attempts have been made to identify 'low risk' patients who may not require traditional, intensive, hospitalized intravenous antimicrobial therapy. Therefore the need for new treatment alternatives for the febrile neutropenic pediatric cancer patient in particular revolves around the desire for less complex regimens, agents with minimal toxicity and expense and the option of an oral formulation for outpatient management. Objective. Fluoroquinolones, especially ciprofloxacin and ofloxacin, are examined in this paper as potential oral alternatives for managing the low risk neutropenic pediatric cancer patient population. Attention must be paid to their antibacterial spectra, however, and in some cases fluoroquinolones should be combined with a second agent for additional Gram-positive coverage. Results. Several studies, including one ongoing trial at the National Cancer Institute, have shown the potential benefits of oral fluoroquinolone therapy among low risk febrile neutropenic patients. Joint complaints in children after ciprofloxacin therapy in the National Cancer Institute trial thus far have been minimal, reversible and felt to be unrelated to ciprofloxacin treatment. Conclusion. The use of outpatient therapy, such as the fluoroquinolones, to manage febrile neutropenic episodes must be approached with caution and should be undertaken only in selected low risk patients.

AB - Background. Empiric antibiotic therapy has become a standard of care for the febrile neutropenic patient. Many clinical trials over the previous three decades have demonstrated that a variety of antibiotic combinations and more recently potent antibiotic monotherapies may preserve the patient through the critical time of fever and neutropenia. Recently attempts have been made to identify 'low risk' patients who may not require traditional, intensive, hospitalized intravenous antimicrobial therapy. Therefore the need for new treatment alternatives for the febrile neutropenic pediatric cancer patient in particular revolves around the desire for less complex regimens, agents with minimal toxicity and expense and the option of an oral formulation for outpatient management. Objective. Fluoroquinolones, especially ciprofloxacin and ofloxacin, are examined in this paper as potential oral alternatives for managing the low risk neutropenic pediatric cancer patient population. Attention must be paid to their antibacterial spectra, however, and in some cases fluoroquinolones should be combined with a second agent for additional Gram-positive coverage. Results. Several studies, including one ongoing trial at the National Cancer Institute, have shown the potential benefits of oral fluoroquinolone therapy among low risk febrile neutropenic patients. Joint complaints in children after ciprofloxacin therapy in the National Cancer Institute trial thus far have been minimal, reversible and felt to be unrelated to ciprofloxacin treatment. Conclusion. The use of outpatient therapy, such as the fluoroquinolones, to manage febrile neutropenic episodes must be approached with caution and should be undertaken only in selected low risk patients.

KW - Fluoroquinolones

KW - cancer

KW - empiric treatment

KW - febrile neutropenia

KW - pediatric

UR - http://www.scopus.com/inward/record.url?scp=0031040769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031040769&partnerID=8YFLogxK

U2 - 10.1097/00006454-199701000-00039

DO - 10.1097/00006454-199701000-00039

M3 - Article

VL - 16

SP - 140

EP - 146

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 1

ER -